Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models

Journal of Pharmacological Sciences

Volumn 111, Issue 1, 2009, Pages 60-72

  Minami, Kazuhisa ^a   Hasegawa, Minoru ^a   Ito, Hisanori ^a   Nakamura, Atsushi ^a   Tomii, Takako ^a   Matsumoto, Mitsunobu ^a   Orita, Satoshi ^a   Matsushima, Syuichi ^a   Miyoshi, Takako ^a   Masuno, Koichi ^a   Torii, Mikinori ^a   Koike, Katsumi ^a   Shimada, Shinji ^a   Kanemasa, Toshiyuki ^a   Kihara, Tsuyoshi ^a   Narita, Minoru ^b   Suzuki, Tsutomu ^b   Kato, Akira ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Bone cancer pain; Fentanyl; Morphine; Neuropathic pain like state; Oxycodone

Indexed keywords

FENTANYL; MORPHINE; OXYCODONE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BIOEQUIVALENCE; BONE CANCER; CANCER PAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; FEMUR; HISTOPATHOLOGY; MALE; MOUSE; NERVE LIGATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN ASSESSMENT; SCIATIC NERVE; TAIL FLICK TEST; TUMOR GROWTH;

ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FENTANYL; MALE; MICE; MICE, INBRED C3H; MICE, INBRED ICR; MORPHINE; OXYCODONE; PAIN; PAIN MEASUREMENT;

EID: 70349506371     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09139FP     Document Type: Article

References (37)

1. Moulin DE, Iezzi A, Amireh R, Sharpe WKJ, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet. 1996;347:143-147. (Pubitemid 26025152)
2. Cherny NI, Thaler HT, Friedlander-Klar H, Lapin J, Foley KM, Houde R, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic pain or nociceptive mechanisms: a combined analysis of controlled single-dose studies. Neurology. 1994;44:857-861. (Pubitemid 24158800)
3. Watson CP, Watt-Watson JH. Treatment of neuropathic pain: focus on antidepressants, opioids and gabapentin. Pain Res Manage. 1999;4:168-178.
4. Smith T, Robert AN. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manage. 2007;3:833-844.
5. Becker R, Jakob D, Uhle EI, Riegel T, Bertalanffy H. The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions. Stereotact Funct Neurosug. 2000;75:16-26.
6. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev. 1998;24:425-432. (Pubitemid 29121682)
7. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-134. (Pubitemid 29199908)
8. Cherny N. New strategies in opioid therapy for cancer pain. J Oncol Manage. 2000;9:8-15.
9. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. Expert Working Group of the Research Network of the European Association for Paliative C. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587-593.
10. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1-18. (Pubitemid 27081402)
11. World Health Organization. Cancer pain relief. Geneva: World Health Organization; 1986.
12. World Health Organization. Cancer pain relief, 2nd ed. Geneva: World Health Organization; 1986.
13. Kalso E. Oxycodone. J Pain Symptom Manage. 2005;29:S47-S56.
14. Bercovitch M, Adunsky A. High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharmacother. 2006;20:33-39. (Pubitemid 46018090)
15. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain. A randomized trial in postherpetic neuralgia. Neurology. 1998;50:1837-1841.
16. Watson CPN, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71-78. (Pubitemid 37162475)
17. Narita M, Nakamura A, Ozaki M, Imai S, Miyoshi K, Suzuki M, et al. Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain like state in mice: evidence for less sensitivity to morphine. Neuropsychopharmacology. 2007;33:1097-1112.
18. Lemberg K, Kontinen VK, Viljakka K, Kylänlahti I, Yli- Kauhaluoma J, Kalso E. Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg. 2006;102:1768-1774. (Pubitemid 43799854)
19. El Mouedden M, Meert TF. Evaluation of pain-related behavior, bone destruction and effectiveness of fentanyl, sufentanil, and morphine in a murine model of cancer pain. Pharmacol Biochem Behav. 2005;82:109-119.
20. Honore P, Lugar NM, Sabino MAC, Schwei MJ, Rogers SD, Mach DB, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neuro-chemical reorganization of the spinal cord. Nat Med. 2000;6: 521-528. (Pubitemid 30305901)
21. Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, et al. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs. inflammatory pain. Pain. 2002;99:397-406.
22. Zhao C, Chen L, Tao YX, Tall JM, Borzan J, RingKamp M, et al. Lumbar sympathectomy attenuates cold allodynia but not mechanical allodynia and hyperalgesia in rats with spared nerve injury. J Pain. 2007;8:931-937. (Pubitemid 350161439)
23. Narita M, Nakajima M, Miyoshi K, Narita M, Nagumo Y, Miyatake M, et al. Role of spinal voltage-dependent calcium channel α2δ-1 subunit in the expression of a neuropathic painlike state in mice. Life Sci. 2007;80:2015-2024. (Pubitemid 46678066)
24. Vermeirsch H, Nuydens RM, Salmon PL, Meert TF. Bone cancer pain model in mice: evaluation of pain behavior, bone destruction and morphine sensitivity. Pharmacol Biochem Behav. 2004;79:243-251. (Pubitemid 40029226)
25. Gilchrist LS, Cain DM, Harding-Rose C, Kov AN, Wendelschafer-Crabb G, Kennedy WR, et al. Re-organization of P2X3 receptor localization on epidermal nerve fivers in a murine model of cancer pain. Brain Res. 2005;1044:197-205. (Pubitemid 40693452)
26. Peters CM, Ghilardi JR, Keyser CP, Kubota K, Lindsay TH, Lugar NM, et al. Tumor-induced injury of primary afferent sensory nerve fivers in bone cancer pain. Exp Neurol. 2005;193: 85-100. (Pubitemid 40463270)
27. Sevcik MA, Ghilardi JR, Peters CM, Limdsay TH, Halvorson KG, Jonas BM, et al. Anti-NGF therapy profoundly reduces bone caner pain and the accompanying increase in markers of peripheral and central sensitization. Pain. 2005;115:128-141. (Pubitemid 40503972)
28. Komiya S, Zenmyo M, Inoue A. Bone tumors in the pelvis presenting growth during pregnancy. Arch Orthop Trauma Surg. 1999;119:22-29. (Pubitemid 29134609)
29. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from opsseous metastases. J Nucl Med. 2004;45:1358-1365. (Pubitemid 47618536)
30. Kirou-Mauro AM, Hird A, Wong J, Sinclair E, Barnes EA, Tsao M. Has pain management in cancer patients with bone metastases improved? A seven-year review at an outpatient palliative radiotherapy clinic. J Pain Symptom Manage. 2009; 37:77-84.
31. Hara S. Opioids for metastatic bone pain. Oncology. 2008;74 Suppl 1:52-54.
32. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain. 2007; 132:289-300. (Pubitemid 350051566)
33. Galandrin S, Oligny-Longpre G, Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci. 2007;28:423-430. (Pubitemid 47087968)
34. Pan YX, Xu J, Moskowitz HS, Xu M, Pasternak GW. Identification of four novel exon 5 splice variants of the mouse μ-opioid receptor gene: functional consequences of C-terminal splicing. Mol Pharmacol. 2005;68:866-875. (Pubitemid 41206043)
35. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matubara T, et al. μ-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci. 2008;108:308-319.
36. Hasbi A, Nguyen T, Fan T, Cheng R, Rashid A, Alijaniaram A, et al. Trafficking of preassembled opioid μ-δ heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists. Biochemistry. 2007;46:12997-13009. (Pubitemid 350086219)
37. Kato A, Minami K, Ito H, Tomii T, Matsumoto M, Orita S, et al. Oxycodone-induced analgesic effects in bone cancer pain model in mice. Oncology. 2008;74 Suppl 1:55-60.